Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 7/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296758 | 0.75 | SCD (0.56) | CHRM4 | |
| SCHEMBL3404141 | 0.73 | POLB (0.53) | HDAC6 | |
| SCHEMBL1816801 | 0.68 | NPC1 (0.59) | EGLN1 | |
| SCHEMBL2290030 | 0.66 | HDAC3 (0.46) | HDAC6ITGB3ITGA2BEGLN1 | |
| SCHEMBL12017926 | 0.65 | EGLN1 (0.45) | CHRM4ITGB3ITGA2BEGLN1 | |
| SCHEMBL26668519 | 0.65 | ITGB3 (0.67) | ITGB3ITGA2B | |
| SCHEMBL8393574 | 0.64 | ACHE (0.69) | CHRM4ITGB3ITGA2B | |
| SCHEMBL7453247 | 0.63 | KDM4E (0.59) | CHRM4HDAC6 | |
| SCHEMBL4924387 | 0.62 | CYP1A2 (0.60) | — | |
| SCHEMBL4633308 | 0.62 | ITGB3 (0.74) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SANOFI-AVENTIS (FR) | 2011-10-06 | — | — | US | disclosed |
| US-8003677-B2 | 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as SCD inhibitors | SANOFI-AVENTIS (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144594-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS | SCD, SCD5, PYCR1 | CHRM4 3959/4885HDAC6 4669/4885ITGB3 2005/4885 |
| US-20110245263-A1 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD | SCD, SCD5, PYCR1 | CHRM4 3498/4885HDAC6 4638/4885ITGB3 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.